New webinar: HER2, CTCs and tumor stemness

BreastCancer_700x233

About 20–30% of breast cancer tumors overexpress the oncogene human epidermal growth factor receptor 2 (HER2), which – if not treated with a targeted anti-HER2 regimen – leads to higher aggressiveness and mortality. Recently, a number of studies have shown that expression of HER2 in circulating tumor cells (CTCs) varies compared to expression in primary tumors. What does this mean for tumor stemness and epithelial-to-mesenchymal transition?

On February 23 and 27, Dr. Siegfried Hauch will present a webinar on HER2 in circulating tumor cells. Check out the abstract below, along with the registration links!


The HER2 miracle in CTCs and its correlation with EMT and tumor stemness

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses. Early detection of breast cancer metastasis would allow for changes in treatment strategy before the disease progression becomes apparent. In this webinar, we will demonstrate  the highly specific, sensitive detection performance for CTC in breast cancer using the AdnaTestBreast.

Using the Combination of Combinations Principle (COCP), AdnaTest BreastCancer enables highly specific immunomagnetic cell selection for enriching circulating tumor cells (CTCs) from peripheral blood. It also allows sensitive analysis of breast cancer-associated gene expression in enriched CTCs by reverse transcription and PCR. The high performance of AdnaTest BreastCancer has been demonstrated in many peer-reviewed studies. Several studies have reported that HER2 expression is different in primary tumors compared to CTCs. In addition, AdnaTestBreast HER2 overexpression profile corresponds to HER2 metastatic phenotype; and HER2 detected by the AdnaTestBreast and AdnaTest EMT-2/StemCell seems to initiate EMT and tumor stemness.

Join Dr. Siegfried Hauch, Director of CTC Research and Product Development at QIAGEN, to learn the technical proof of the AdnaTest BreastCancer technology and the comparison study of the AdnaTest BreastCancer vs. the FDA-cleared CELLSEARCH® system.

Speaker: Dr. Siegfried Hauch
Webinar date: Thu, Feb 23, 2017 1:00 p.m. – 2:00 p.m. EST
Registration link: https://attendee.gotowebinar.com/register/418399739084785155

Webinar date: Mon, Feb 27, 2017 9:30 a.m. – 10:30 a.m. EST
Registration link: https://attendee.gotowebinar.com/register/1038375863080706819

 

Ali Bierly

Ali Bierly, PhD is a Global Market Manager in Translational Sciences at QIAGEN, and has written on a number of scientific topics in the biotech industry as the author of QIAGEN's Reviews Online. She received her PhD from Cornell University in 2009, studying the immune response to a protozoan parasite, Toxoplasma gondii. Ali has a keen interest in the emerging importance of microRNA and other circulating nucleic acids as biomarkers for disease.

Your email address will not be published. Required fields are marked *